- 1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal
- 2Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 3Department of Neuroscience and Mental Health, Neurology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
- 4Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Citation: Oliveira SR, Dionísio PA, Gaspar MM, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ, Amaral JD and Rodrigues CMP (2021) miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease. Front. Cell Dev. Biol. 9:661461. doi: 10.3389/fcell.2021.661461
Received: 30 January 2021; Accepted: 19 May 2021;
Published: 15 June 2021; Retracted: 06 October 2025.
Edited by:
Diego Franco, University of Jaén, SpainReviewed by:
Isabella Russo, University of Turin, ItalyYehong Du, Chongqing Medical University, China
Wanli Smith, Johns Hopkins University, United States